Lipidomics to Assess Omega 3 Bioactivity
AbstractHow can we resolve the conflict between the strong epidemiological evidence pointing to the usefulness of fish—and, thus, omega 3—consumption with the debacle of supplementation trials? One potential explanation is that the null results obtained thus far are the consequences of ill-contrived investigations that do not allow us to conclude on the effects (or lack thereof) of omega 3 fatty acid supplementation. One potential solution is through the use of lipidomics, which should prove very useful to screen suitable patients and to correlate plasma (or red blood cells, or whole blood, or phospholipid) fatty acid profile with outcomes. This has never been done in omega 3 trials. The wise use of lipidomics should be essential part of future omega 3 trials and would help in untangling this current riddle. View Full-Text
Share & Cite This Article
Visioli, F. Lipidomics to Assess Omega 3 Bioactivity. J. Clin. Med. 2015, 4, 1753-1760.
Visioli F. Lipidomics to Assess Omega 3 Bioactivity. Journal of Clinical Medicine. 2015; 4(9):1753-1760.Chicago/Turabian Style
Visioli, Francesco. 2015. "Lipidomics to Assess Omega 3 Bioactivity." J. Clin. Med. 4, no. 9: 1753-1760.